About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Mineralys Therapeutics, Inc. (MLYS): Insider Trades and Fund Holdings
In the past 12 months, Mineralys Therapeutics, Inc. insiders reported no open-market purchases and 17 sales worth $11.7M; 16 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Oct 19, 2026NewsCompany reported: Executive or director change
- Oct 13, 2026Planned saleRodman David Malcom (officer) filed notice to sell about $78,066 around Oct 13, 2026
- Sep 30, 2026Insider saleCEO Jon Congleton sold $1.9 million under a 10b5-1 plan
- Sep 30, 2026Planned saleCongleton Jon (officer, director) filed notice to sell about $1.9 million around Sep 30, 2026
- Sep 22, 2026Insider saleDirector Brian Taylor Slingsby sold $3 million
- Sep 22, 2026Planned saleCATALYS PACIFIC FUND LP (director) filed notice to sell about $3 million around Sep 22, 2026
- Sep 21, 2026Insider saleChief Commercial Officer Eric Warren sold $209,136 under a 10b5-1 plan
- Sep 21, 2026Planned saleWarren Eric (officer) filed notice to sell about $209,135 around Sep 21, 2026
- Sep 17, 2026Planned saleRodman David Malcom (officer) filed notice to sell about $11,655 around Sep 17, 2026
- Sep 15, 2026Insider saleDirector Daphne Karydas sold $85,740 under a 10b5-1 plan
- Sep 15, 2026Planned saleKarydas Daphne (officer) filed notice to sell about $85,740 around Sep 15, 2026
- Sep 14, 2026Planned saleRodman David Malcom (officer) filed notice to sell about $216,931 around Sep 14, 2026
- Sep 9, 2026Planned saleRodman David Malcom (officer) filed notice to sell about $67,019 around Sep 9, 2026
- Aug 21, 2026Insider saleChief Commercial Officer Eric Warren sold $193,189 under a 10b5-1 plan
- Aug 21, 2026Planned saleWarren Eric (officer) filed notice to sell about $193,188 around Aug 21, 2026
- Aug 17, 2026Planned saleRodman David Malcom (officer) filed notice to sell about $10,617 around Aug 17, 2026
- Aug 10, 2026Insider saleChief Medical Officer David Malcom Rodman sold $58,785 under a 10b5-1 plan
- Jul 21, 2026Insider saleChief Commercial Officer Eric Warren sold $199,885 under a 10b5-1 plan
- Jul 17, 2026Insider saleChief Medical Officer David Malcom Rodman sold $11,036 under a 10b5-1 plan
- Jul 15, 2026Insider saleChief Medical Officer David Malcom Rodman sold $168,955 under a 10b5-1 plan
- Jul 13, 2026Insider saleChief Medical Officer David Malcom Rodman sold $387,717 under a 10b5-1 plan
- Jul 13, 2026Insider saleCEO Jon Congleton sold $291,441 under a 10b5-1 plan
- Jul 9, 2026Insider saleChief Medical Officer David Malcom Rodman sold $65,781 under a 10b5-1 plan
- Jun 30, 2026Insider saleCEO Jon Congleton sold $2 million under a 10b5-1 plan
- Jun 30, 2026FundRenaissance Technologies cut 1% in Q2 2026 (13F filed Aug 13, 2026)
- Jun 26, 2026Insider saleChief Commercial Officer Eric Warren sold $2.7 million under a 10b5-1 plan
- Jun 17, 2026Insider saleChief Medical Officer David Malcom Rodman sold $114,600 under a 10b5-1 plan
- Jun 17, 2026Insider saleDirector Daphne Karydas sold $75,000 under a 10b5-1 plan
- Jun 15, 2026Insider saleChief Medical Officer David Malcom Rodman sold $235,487 under a 10b5-1 plan
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 2, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 2 | Jon CongletonCEO | ▼ SELL10b5-1 | $1.91M |
| Sep 24 | Brian Taylor SlingsbyDirector | ▼ SELL | $3.01M |
| Sep 22 | Eric WarrenChief Commercial Officer | ▼ SELL10b5-1 | $209K |
| Sep 17 | Daphne KarydasDirector | ▼ SELL10b5-1 | $86K |
| Aug 25 | Eric WarrenChief Commercial Officer | ▼ SELL10b5-1 | $193K |
| Aug 12 | David Malcom RodmanChief Medical Officer | ▼ SELL10b5-1 | $59K |
| Jul 23 | Eric WarrenChief Commercial Officer | ▼ SELL10b5-1 | $200K |
| Jul 20 | David Malcom RodmanChief Medical Officer | ▼ SELL10b5-1 | $11K |
| Jul 15 | David Malcom RodmanChief Medical Officer | ▼ SELL10b5-1 | $388K |
| Jul 15 | Jon CongletonCEO | ▼ SELL10b5-1 | $291K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Jon Congleton | CEO | 0 | $0 | 3 | $4.16M |
| Brian Taylor Slingsby | Director | 0 | $0 | 1 | $3.01M |
| Eric Warren | Chief Commercial Officer | 0 | $0 | 4 | $3.30M |
| Daphne Karydas | Director | 0 | $0 | 2 | $161K |
| David Malcom Rodman | Chief Medical Officer | 0 | $0 | 7 | $1.04M |
A All 17 insider trades reported on time. How it is graded
Tracked funds that report MLYS
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 378,300 | $10.2M | ▼ −1.2% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →